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Association of Aspirin Use With Mortality Risk Among Older Adult Participants
in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
Holli A. Loomans-Kropp, PhD, MPH; Paul Pinsky, PhD; Yin Cao, ScD, MPH; Andrew T. Chan, MD, MPH; Asad Umar, PhD, DVM

Abstract
IMPORTANCE Aspirin use has been associated with reduced risk of cancer mortality, particularly of
the colorectum. However, aspirin efficacy may be influenced by biological characteristics, such as

Key Points
Question Is aspirin use associated with
reduced risk of mortality in older adults?

obesity and age. With the increasing prevalence of obesity and conflicting data regarding the effect

Findings This cohort study included

of aspirin in older adults, understanding the potential association of aspirin use with cancer mortality

146 152 individuals from the Prostate,

according to body mass index (BMI) and age is imperative.

Lung, Colorectal, and Ovarian Cancer
Screening Trial and found that aspirin

OBJECTIVES To investigate the association of aspirin use with risk of all-cause, any cancer,

use 3 or more times per week was

gastrointestinal (GI) cancer, and colorectal cancer (CRC) mortality among older adults and to perform

associated with reduced risk of

an exploratory analysis of the association of aspirin use with mortality stratified by BMI.

all-cause, cancer, gastrointestinal
cancer, and colorectal cancer mortality.

DESIGN, SETTING, PARTICIPANTS This cohort study evaluated aspirin use among participants
aged 65 years and older in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
at baseline (November 8, 1993, to July 2, 2001) and follow-up (2006-2008). Analysis began in late

Meaning These findings suggest that
prophylactic aspirin use may reduce risk
of mortality among older individuals.

2018 and was completed in September 2019.
MAIN OUTCOMES AND MEASURES All-cause, any cancer, GI cancer, or CRC mortality. Multivariable
hazard ratios (HRs) and 95% CIs were calculated using time-varying Cox proportional hazards
regression modeling, adjusting for additional factors.

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

RESULTS A total of 146 152 individuals (mean [SD] age at baseline, 66.3 [2.4] years; 74 742 [51.1%]
women; 129 446 [88.6%] non-Hispanic white) were included in analysis. The median (interquartile
range) follow-up time was 12.5 (8.7-16.4) years, encompassing 1 822 164 person-years. Compared
with no use, aspirin use 1 to 3 times per month was associated with reduced risk of all-cause mortality
(HR, 0.84; 95% CI, 0.80-0.88; P < .001) and cancer mortality (HR, 0.87; 95% CI, 0.81-0.94;
P < .001). Aspirin use 3 or more times per week was associated with decreased risk of mortality of all
causes (HR, 0.81; 95% CI, 0.80-0.83; P < .001), any cancer (HR, 0.85; 95% CI, 0.81-0.88; P < .001),
GI cancer (HR, 0.75; 95% CI, 0.66-0.84; P < .001), and CRC (HR, 0.71; 95% CI, 0.61-0.84; P < .001).
When stratified by BMI (calculated as weight in kilograms divided by height in meters squared),
aspirin use 3 or more times per week among individuals with BMI 20 to 24.9 was associated with
reduced risk of all-cause mortality (HR, 0.82; 95% CI, 0.78-0.85; P < .001) and any cancer mortality
(HR, 0.86; 95% CI, 0.79-0.92; P < .001). Among individuals with BMI 25 to 29.9, aspirin use 3 or more
times per week was associated with reduced risk of all-cause mortality (HR, 0.82; 95% CI, 0.79-0.85;
P < .001), any cancer mortality (HR, 0.86; 95% CI, 0.81-0.91; P < .001), GI cancer mortality (HR, 0.72;
95% CI, 0.60-0.86; P < .001), and CRC mortality (HR, 0.66; 95% CI, 0.51-0.85; P = .001).
CONCLUSIONS AND RELEVANCE In this cohort study, aspirin use 3 or more times per week was
associated with a reduction in all-cause, cancer, GI cancer and CRC mortality in older adults.
JAMA Network Open. 2019;2(12):e1916729.
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Introduction
Aspirin use of 10 years or more is estimated to reduce cancer incidence and mortality.1-4 Across
epidemiological studies, the most significant reductions in risk have been noted in gastrointestinal
(GI) cancers.2,4 Notably, results from the NIH-AARP study,5 the Nurses’ Health Study,6 and Health
Professionals Follow-up Study7,8 demonstrated that long-term regular aspirin use was associated
with reduced risk of obesity- and inflammation-associated cancers, particularly colorectal cancer
(CRC). This result has been additionally illustrated in a 2010 meta-analysis of randomized clinical
trials.4 The association of aspirin with reduced cancer incidence and mortality has been consistently
robust among GI cancers; however, there is limited evidence suggesting that aspirin use is associated
with reduced mortality risk among other cancer types.3,9-11 The US Preventive Services Task Force
(USPSTF) recommends low-dose aspirin use for the prevention of cardiovascular disease and CRC
among average-risk individuals aged 50 to 59 years with a 10% or greater 10-year risk of
cardiovascular disease; however, individuals aged 60 to 69 years should have an individualized
approach, while evidence for use among individuals 70 years and older remains insufficient.12 It is
important to note that a 2015 systematic review of the literature by the USPSTF11 found that
individuals with daily aspirin dosing up to 1200 mg for a duration of 4 or more years exhibited a
significant reduction in all-cause and cancer mortality, demonstrating a similar benefit of low-dose
and standard aspirin.
Recently, the results of the Aspirin in Reducing Events in the Elderly (ASPREE) study13 drew
further attention of the potential cancer preventive effect of aspirin. The ASPREE study was a
randomized clinical trial conducted in the United States and Australia investigating the efficacy of
100 mg of aspirin daily vs placebo in extending disability-free survival among elderly individuals
(recruitment age 65 years or 70 years) during 4.7 years of follow-up.13 Unexpectedly, an increased
risk of all-cause and cancer-related death was observed in the group randomized to aspirin.14
Thus, based on the results of the ASPREE randomized clinical trial that conflict with the
preponderance of data showing a benefit of aspirin use, we examined the association of aspirin use
with mortality risk among older adults enrolled in the Prostate, Lung, Colorectal, and Ovarian (PLCO)
Cancer Screening Trial. In addition, given data suggesting that aspirin may be less effective among
individuals who are overweight or obese, we conducted exploratory analyses stratified by body mass
index (BMI), calculated as weight in kilograms divided by height in meters squared.1

Methods
This study is a post hoc analysis of PLCO study data. The original trial was approved by the
institutional review boards at all study sites (University of Alabama at Birmingham, Georgetown
University, University of Pittsburgh, Washington University in St. Louis, University of Utah, University
of Colorado, University of Minnesota, Pacific Health Research and Education Institute, Henry Ford
Health System, and Marshfield Clinic Research Foundation). All enrolled participants provided
written informed consent. The use of their data for additional studies and analysis was included in the
original informed consent. This study adhered to the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) reporting guideline.

Study Design
The design and methods of the PLCO Cancer Screening Trial have been previously described.15,16
Briefly, participants aged 55 to 74 years were randomized to the intervention (screening) or control
arm at 10 screening centers in the United States between November 8, 1993, and July 2, 2001.
Pertinent exclusion criteria for this study were individuals with a history of CRC or lung, prostate, or
ovarian cancer, previous surgical removal of the colon, lung, or prostate, or, starting in 1995,
individuals who had a colonoscopy, sigmoidoscopy, or barium enema in the 3 years prior to study
randomization. This cohort included participants who were 65 years or older or survived until age 65,
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had a valid baseline questionnaire (BQ) after study enrollment, and had reported information on
aspirin use at baseline. Completion of a follow-up supplemental questionnaire (SQ) by participants
between 2006 and 2008 was not required for inclusion into the study cohort. All responses to the
BQ and SQ were ascertained by self-report. The full content of both questionnaires has been
published previously.17,18 Briefly, the BQ asked, “During the last 12 months, have you regularly used
aspirin or aspirin-containing products, such as Bayer, Bufferin, or Anacin (Please do not include
aspirin-free products such as Tylenol and Panadol).” If the respondent answered yes, the frequency
categories were given as less than 2 per month, 2 to 3 per month, 1 per week, 2 per week, 3 to 4 per
week, 1 per day, or 2 or more per day. The SQ asked, “During the last 12 months, about how often did
you usually take aspirin (examples of aspirin include Bayer, Bufferin, Anacin, and baby aspirin)?” The
frequency categories were given as none or less than once per month, 1 to 3 times per month, 1 to 2
times per week, 3 to 6 times per week, and 7 or more times per week. To allow for consistent values
between BQs and SQs, we collapsed the aspirin use frequency variables into no aspirin use or less
than once per month, 1 to 3 times per month, 1 to 2 times per week, and 3 or more times per week.
Usual dose information was not available on the BQ; therefore, this analysis does not consider dose.
We categorized BMI as less than 20, 20 to 24.9, 25 to 29.9, and 30 or higher.
Initial analysis of the PLCO Cancer Screening Trial was completed after 13 years of follow-up or
on December 31, 2009, whichever came first.15 Deaths were ascertained via annual study update
questionnaire, individual reports, or death certificates. Beginning in 2011, participants were
reconsented for follow-up. This allowed for linkage to the National Death Index, which extended
mortality follow-up for up to 20 years after randomization.19 For those reconsenting, the end of
mortality follow-up was December 31, 2015 or their date of death, whichever came first. For the
approximately 15% of individuals who were alive in 2011 but who declined extended follow-up, the
end of mortality follow-up was their declining date, which was generally in 2011.

Statistical Analysis
The purpose of this analysis was to assess the associations among aspirin use, BMI, and mortality of
all causes, any cancer, gastrointestinal (GI) cancer, and CRC among individuals in the PLCO Cancer
Screening Trial who survived to age 65 years and older (Figure 1). Participant follow-up time was
measured from the time of cohort entry, which was either the date of PLCO Cancer Screening Trial

Figure 1. Flowchart of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Cohort Used
in the Study Analysis
154 897 Total of Prostate, Lung, Colorectal,
and Ovarian Cancer Screening Trial population

146 370 Participants surviving to age 65 y

146 152 Completed aspirin questionnaire at baseline

105 733 No death reported during follow-up

40 419 Death reported during follow-up

12 421 Cancer death

1425 Gastrointestinal cancer death

27 998 Noncancer death

10 996 Other cancer death

814 Colorectal cancer death
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enrollment or age 65 years, whichever occurred last, until the date of death or December 31, 2015,
whichever came first. Survival time was measured from the time of cohort entry, until time of death
of any cause. Hazard ratios (HRs) were calculated using Cox proportional hazards regression models
to analyze the associations among aspirin use (no use, 1-3 times per month, 1-2 times per week, and
ⱖ3 times per week), BMI (<20, 20-24.9, 25-29.9, ⱖ30), and mortality, controlling for covariates. As
aspirin use, BMI, and other covariates may have changed between completion of the BQ and SQ,
time-varying proportional hazards models were used. Initial aspirin use and covariate values were
taken from the BQ for participants 65 years or older at randomization and for participants younger
than 65 years at randomization who either did not fill out the SQ or filled it out after reaching age 65
years; initial values were taken from the SQ for those younger than 65 years at randomization
completing the SQ before age 65 years. Among those with initial aspirin use and covariate values
taken from the BQ and who also completed the SQ, values were updated at that time to the
corresponding SQ values. Time-varying variables included in the model were aspirin use, BMI,
smoking status (ie, never, current, or former smoker), history of myocardial infarction, history of
stroke, history of hypertension, history of diabetes, and ibuprofen use 3 or more times per week.
Static variables included in the models were sex (male or female), race/ethnicity (white non-Hispanic,
black non-Hispanic, or other), and randomization arm (intervention or control). We additionally
stratified by BMI to evaluate the association of aspirin use and BMI with mortality.
Finally, as an exploratory assessment of longitudinal patterns of aspirin use, we examined risk of
mortality only among participants who had completed aspirin frequency questions on the BQ and
SQ. Follow-up for this cohort subset began at age 65 years or completion of the SQ, whichever
occurred last. Participants were categorized according to baseline and follow-up aspirin use as (1)
consistent nonusers (use >1 time per week or no use at baseline and follow-up), (2) users at baseline
only (use ⱖ1 time per week at baseline only), (3) users at follow-up only (use ⱖ1 time per week at
follow-up only), or (4) consistent users (use ⱖ1 time per week at baseline and follow-up). We used
weekly aspirin use as our metric in this analysis for consistency with previous analyses and to include
the maximum number of participants with BQ and SQ data. Supplemental questionnaire variables
included in the model were randomization arm, sex (male or female), race/ethnicity (white
non-Hispanic, black non-Hispanic, or other), BMI, smoking status (never, current, or former smoker),
history of myocardial infarction, history of stroke, history of hypertension, history of diabetes, and
ibuprofen use 3 or more times per week.
Causes of death were determined by International Classification of Diseases, Ninth Revision
(ICD-9) codes.20 All-cause mortality was defined as a reported death of any cause. Any cancer
mortality was defined as a reported cause of death by cancer based on the official PLCO Cancer
Screening Trial definitions, derived from standard ICD-9 groupings. Cause of death by GI cancer was
determined by ICD-9 codes for esophagus (150), gastric (151), and colorectal (153 and 154) cancer,
whereas CRC was determined by ICD-9 codes for CRC only (153 and 154). All statistical analyses were
performed in SAS statistical software version 9.4 (SAS Institute). P values were 2-tailed, and statistical
significance was set at less than .05.

Results
The eligibility criteria for the study analysis are outlined in Figure 1. After excluding individuals who
died before age 65 years, there were 146 152 participants (mean [SD] age at baseline, 66.3 [2.4]
years; 74 742 [51.1%] women; 129 446 [88.6%] non-Hispanic white) included in our analysis. The
mean (SD) duration from baseline to completing the SQ was 9.1 (1.9) years and the median (range)
was 9.2 (4.6-14.2) years, with a median (interquartile range) follow-up time of 12.5 8.7-16.4) years.
Among the total cohort included in our study, 40 419 individuals (27.7%) died during follow-up,
including 12 421 individuals (30.7%) who died of any cancer, 1425 individuals (3.5%) who died of GI
cancers (including 353 individuals with esophageal cancer [2.8%] and 258 individuals with gastric
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cancer [2.1%]), and 814 individuals (6.6%) who died of CRC. Demographic characteristics of the
cohort are summarized in Table 1.
The results of the Cox proportional hazards regression model are presented in Table 2. In our
model, any aspirin use was associated with reduced all-cause and cancer-specific mortality. Reduced
risk of all-cause mortality was associated with using aspirin 1 to 3 times per month (HR, 0.84; 95%

Table 1. Characteristics of 146 152 Participants at Baseline
No. (%)
Mortality
Characteristic

Totala,b

No Reported Death

All-Cause

Cancer

GI Cancer

CRC

No.

146 152

105 728

40 419

12 421

1425

814

65b

100 046 (68.5)

81 933 (77.5)

18 113 (44.8)

6631 (53.4)

735 (51.6)

414 (50.9)

66-69

26 116 (17.9)

15 348 (14.5)

10 768 (26.6)

3138 (25.3)

359 (25.2)

209 (25.7)

70-74

19 981 (13.7)

8449 (8.0)

11 532 (28.5)

2651 (21.3)

330 (23.2)

190 (23.3)

≥75

9 (0.0)

3 (0.0)

6 (0.0)

1 (0.0)

1 (0.1)

1 (0.1)

Men

71 410 (48.9)

47 090 (44.5)

24 320 (60.2)

7410 (59.7)

957 (67.2)

489 (60.1)

Women

74 742 (51.1)

58 643 (55.5)

16 099 (39.8)

5019 (40.3)

468 (32.8)

325 (39.9)

White

129 446 (88.6)

94 034 (88.9)

35 412 (87.6)

10 929 (88.0)

1202 (84.4)

690 (84.8)

Black

7285 (5.0)

4731 (4.5)

2554 (6.3)

765 (6.2)

109 (7.7)

66 (8.1)

9421 (6.5)

6968 (6.6)

2453 (6.1)

727 (5.9)

114 (8.0)

58 (7.1)

Age, y

Sex

Race/ethnicity
Non-Hispanic

Otherc
Randomization group
Intervention

73 827 (50.5)

53 431 (50.5)

20 396 (50.5)

6262 (50.4)

646 (45.3)

349 (42.9)

Control

72 325 (49.5)

52 302 (49.5)

20 023 (49.5)

6159 (49.6)

779 (54.7)

465 (57.1)

335 (41.2)

Smoking status
Never

68 103 (46.6)

53 162 (50.3)

14 941 (37.0)

4023 (32.4)

519 (36.5)

Current

150 022 (10.3)

8622 (8.2)

6400 (15.8)

2455 (19.8)

188 (13.2)

90 (11.1)

Former

63 007 (43.1)

43 938 (42.6)

19 069 (472)

5942 (47.8)

717 (50.4)

389 (47.8)

3945 (2.7)

2603 (2.5)

1342 (3.3)

359 (2.9)

36 (2.6)

19 (2.3)

20-24.9

44 573 (30.5)

32 924 (31.1)

11 649 (28.8)

3646 (29.4)

383 (27.3)

222 (27.3)

25-29.9

61 114 (41.8)

44 481 (42.1)

16 633 (41.2)

5305 (42.7)

609 (43.4)

332 (40.8)

≥30

34 493 (23.6)

24 375 (23.1)

10 118 (25.0)

2926 (23.6)

374 (26.7)

225 (27.6)

None or <1/mo

74 908 (51.3)

55 701 (52.7)

19 207 (47.5)

6214 (50.0)

733 (51.4)

430 (52.8)

1-3/mo

14 451 (9.9)

10 921 (10.3)

3530 (8.7)

1188 (9.6)

129 (9.1)

81 (10.0)

1-2/wk

6650 (4.6)

5151 (4.9)

1499 (3.7)

502 (4.0)

61 (4.3)

34 (4.2)

≥3/wk

50 143 (34.3)

33 960 (32.1)

16 183 (40.0)

4517 (36.4)

502 (35.2)

269 (33.1)

Body mass indexd
<20

Reported aspirin use in the last 12 mo

Abbreviations: CRC, Colorectal Cancer; GI, gastrointestinal.
a

Smoking status missing from total cohort (n = 20).

b

Body mass index status missing from total cohort (n = 2027).

c

Aggregate of Hispanic, Asian, Pacific Islander, and American Indian, owing to low
study numbers.

d

Calculated as weight in kilograms divided by height in meters squared.

Table 2. Updated Aspirin Use and All-Cause, Cancer, GI Cancer, and CRC Mortality Among Individuals
Aged 65 Years and Older
Mortality, Hazard Ratio (95% CI)a

Reported Aspirin
Use

All-Cause

Cancer

GI Cancer

CRC

None

1 [Reference]

1 [Reference]

1 [Reference]

1 [Reference]

1-3/mo

0.84 (0.80-0.88)

0.87 (0.81-0.94)

0.84 (0.68-1.05)

0.90 (0.69-1.19)

1-2/wk

0.85 (0.81-0.90)

0.90 (0.82-1.00)

0.90 (0.68-1.19)

0.75 (0.50-1.12)

≥3/wk

0.81 (0.79-0.83)

0.85 (0.81-0.88)

0.75 (0.66-0.84)

0.71 (0.61-0.84)
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CI, 0.80-0.88; P < .001), 1 to 2 times per week (HR, 0.86; 95% CI, 0.81-0.90; P < .001), or 3 or more
times per week (HR, 0.81; 95% CI, 0.80-0.83; P < .001). A similar association was noted for risk of
cancer mortality and aspirin use 1 to 3 times per month (HR, 0.87; 95% CI, 0.81-0.94; P < .001) or 3 or
more times per week (HR, 0.85; 95% CI, 0.81-0.88; P < .001). Use of aspirin 3 or more times per
week was also associated with significantly reduced risk of GI cancer mortality (HR, 0.75; 95% CI,
0.66-0.84; P < .001) and CRC mortality (HR, 0.71; 95% CI, 0.61-0.84; P < .001). Data for the
additional covariates included in the model are provided in the eTable in the Supplement.
To explore the potential association of aspirin use and BMI with mortality risk, we stratified the
cohort according to BMI. The results are shown in Figure 2. Compared with no aspirin use and among
individuals with a BMI of 20 or higher, aspirin use was associated with reduced risk of all-cause
mortality when used 1 to 3 times per month (BMI 20-24.9: HR, 0.83; 95% CI, 0.76-0.89; P < .001;

Figure 2. Adjusted Hazard Ratios (HRs) and 95% CIs for Mortality by Aspirin Use Stratified by Body Mass Index (BMI)
A All-cause mortality

Aspirin Use

B

Does Not
Favor
Mortality

HR
(95% CI)

Favors
Mortality

P Value

1-3 Times/mo, BMI

Cancer mortality

Aspirin Use

Does Not
Favor
Mortality

HR
(95% CI)

Favors
Mortality

P Value

1-3 Times/mo, BMI

<20

0.92 (0.73-1.15)

.46

<20

0.82 (0.53-1.27)

.37

20-24.9

0.83 (0.76-0.89)

<.001

20-24.9

0.83 (0.72-0.95)

.007

25-29.9

0.82 (0.78-0.93)

<.001

25-29.9

0.89 (0.80-1.00)

.049

≥30

0.85 (0.78-0.93)

<.001

≥30

0.85 (0.72-1.00)

.046

1-2 Times/wk, BMI

1-2 Times/wk, BMI

<20

0.98 (0.74-1.31)

.89

<20

0.88 (0.50-1.54)

.64

20-24.9

0.85 (0.77-0.94)

.002

20-24.9

0.95 (0.80-1.12)

.52

25-29.9

0.85 (0.78-0.93)

.001

25-29.9

0.86 (0.74-1.00)

.05

≥30

0.86 (0.76-0.96)

.01

≥30

1.00 (0.82-1.22)

.90

≥3 Times/wk, BMI

≥3 Times/wk, BMI

<20

0.95 (0.83-1.07)

.39

<20

0.87 (0.67-1.11)

.25

20-24.9

0.82 (0.78-0.85)

<.001

20-24.9

0.86 (0.79-0.92)

<.001

25-29.9

0.82 (0.79-0.85)

<.001

25-29.9

0.86 (0.81-0.91)

<.001

≥30

0.78 (0.75-0.82)

<.001

≥30

0.81 (0.75-0.88)

<.001

0.1

1

10

0.1

HR (95% CI)

C

10

D Colorectal cancer mortality

Gastrointestinal cancer mortality

Aspirin Use

1

HR (95% CI)

Does Not
Favor
Mortality

HR
(95% CI)

Favors
Mortality

P Value

1-3 Times/mo, BMI

Aspirin Use

Does Not
Favor
Mortality

HR
(95% CI)

Favors
Mortality P Value

1-3 Times/mo, BMI

<20

0.60 (0.14-2.57)

.49

<20

0.59 (0.08-4.57)

.61

20-24.9

0.71 (0.44-1.12)

.14

20-24.9

0.92 (0.53-1.58)

.76

25-29.9

0.93 (0.68-1.27)

.65

25-29.9

1.02 (0.68-1.53)

.92

≥30

0.80 (0.51-1.26)

.33

≥30

0.65 (0.35-1.21)

.18

1-2 Times/wk, BMI

1-2 Times/wk, BMI

<20

1.17 (0.27-5.08)

.83

<20

1.15 (0.15-8.99)

.90

20-24.9

1.40 (0.90-2.19)

.14

20-24.9

1.29 (0.71-2.35)

.41

25-29.9

0.69 (0.43-1.11)

.13

25-29.9

0.61 (0.31-1.20)

.15

≥30

0.80 (0.43-1.47)

.47

≥30

0.45 (0.17-1.23)

.12

≥3 Times/wk, BMI

≥3 Times/wk, BMI

<20

0.57 (0.24-1.35)

.20

<20

0.38 (0.10-1.47)

.16

20-24.9

0.79 (0.62-1.00)

.049

20-24.9

0.76 (0.56-1.04)

.08

25-29.9

0.72 (0.60-0.86)

<.001

25-29.9

0.66 (0.51-0.85)

.001

≥30

0.79 (0.63-1.00)

.05

≥30

0.77 (0.57-1.03)

.08

0.1

1

10

HR (95% CI)

0.01

0.1

1

10

HR (95% CI)

No aspirin use was used as the reference for all comparisons. The model was adjusted for sex, race/ethnicity, randomization group, smoking status, ibuprofen use 3 times or more per
week, and history of myocardial infarction, stroke, hypertension, and diabetes. Body mass index was calculated as weight in kilograms divided by height in meters squared.
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BMI 25-29.9: HR, 0.82; 95% CI, 0.78-0.93; P < .001; BMI ⱖ30: HR, 0.85; 95% CI, 0.78-0.93;
P < .001), 1 to 2 times per week (BMI 20-24.9: HR, 0.85; 95% CI, 0.77-0.94; P = .002; BMI 25-29.9:
HR, 0.85; 95% CI, 0.78-0.93; P = .001; BMI ⱖ30: HR, 0.86; 95% CI, 0.76-0.96; P = .01), or 3 or more
times per week (BMI 20-24.9: HR, 0.82; 95% CI, 0.78-0.85; P < .001; BMI 25-29.9: HR, 0.82; 95%
CI, 0.79-0.85; P < .001; BMI ⱖ30: HR, 0.78; 95% CI, 0.75-0.82; P < .001) (Figure 2A). Reduced risk of
cancer-specific mortality was noted among individuals with reported aspirin use 3 or more times per
month and BMI 20 to 24.9 (HR, 0.86; 95% CI, 0.79-0.92; P < .001), BMI 25-29.9 (HR, 0.86; 95% CI,
0.81-0.91; P < .001) or BMI 30 or higher (HR, 0.81; 95% CI, 0.75-0.88; P < .001) (Figure 2B). No
statistically significant risk reduction was observed for cancer mortality among participants who used
aspirin 1 to 2 times per week or 1 to 3 times per month, except for aspirin use 1 to 3 times per month
among individuals with BMI 20 to 24.9 (HR, 0.83; 95% CI, 0.72-0.95; P = .007) (Figure 2B).
Individuals with BMI 25 to 29.9 who used aspirin 3 or more times per week were associated with
reduced risk of GI cancer mortality (HR, 0.72; 95% CI, 0.60-0.86; P < .001) and CRC mortality (HR,
0.66; 95% CI, 0.51-0.85; P < .001) (Figure 2C and D).
We additionally examined the association between reported aspirin use at baseline and at the
time of the SQ with risk of mortality. Participants who had reported aspirin use at follow-up only or
consistent users were associated with a reduced risk of mortality (Table 3). Individuals who reported
aspirin use at follow-up only were associated with reduced risk of all-cause mortality (HR, 0.79; 95%
CI, 0.76-0.82; P < .001), cancer mortality (HR, 0.82; 95% CI, 0.76-0.88; P < .001), and GI cancer
mortality (HR, 0.74; 95% CI, 0.59-0.94; P = .01). Individuals who were consistent aspirin users were
also associated with reduced risk of all-cause mortality (HR, 0.80; 95% CI, 0.76-0.83; P < .001),
cancer mortality (HR, 0.77; 95% CI, 0.72-0.83; P < .001), and GI cancer mortality (HR, 0.75; 95% CI,
0.59-0.94; P = .01). Of particular interest, the HRs for CRC-associated mortality were 0.88 (95% CI,
0.58-1.33; P = .53) for users at baseline only, 0.62 (95% CI, 0.46-0.85; P = .003) for users at
follow-up only, and 0.62 (95% CI, 0.46-0.85; P = .003) for consistent users, compared with nonusers
of aspirin.

Discussion
This cohort study found that aspirin use among individuals 65 years and older was associated with a
lower risk of mortality. This observation was consistent across all causes of mortality (ie, all-cause,
cancer, GI cancer, and CRC); however, the greatest reduction in risk was noted for CRC mortality
among individuals who used aspirin 3 or more times per week. Additionally, our exploratory analyses
investigating the potential associations among aspirin use, BMI, and mortality risk suggest that the
efficacy of aspirin as a cancer preventive agent may be associated with BMI. Participants in the PLCO
Cancer Screening Trial who were underweight (ie, BMI <20) had no observable benefit associated
with aspirin use, while those with BMI 20 or higher were associated with reduced mortality risk,

Table 3. Baseline and Follow-up Aspirin Use and Risk of All-Cause, Any Cancer, GI Cancer, and CRC Mortality Among Individuals Aged 65 Years and Older
Mortalitya
All-Cause
Reported Aspirin Use

No.

Deaths

Total

101 098

17 610

Cancer
HR (95% CI)

Deaths

GI Cancer
HR (95% CI)

5396

Deaths

CRC
HR (95% CI)

559

Deaths

HR (95% CI)

308

Consistent nonusers

32 658

5185

1 [Reference]

1771

1 [Reference]

189

1 [Reference]

117

1 [Reference]

Users at baseline

9259

2015

1.06 (1.00-1.12)

570

0.99 (0.90-1.10)

67

1.10 (0.82-1.48)

35

0.88 (0.58-1.33)

Users at follow-up

27 583

4804

0.79 (0.76-0.82)

1497

0.82 (0.76-0.88)

148

0.74 (0.59-0.94)

80

0.62 (0.46-0.85)

Consistent users

28 186

5606

0.80 (0.76-0.83)

1558

0.77 (0.72-0.83)

155

0.75 (0.59-0.94)

76

0.62 (0.46-0.85)

Abbreviations: CRC, colorectal cancer; GI, gastrointestinal; HR, hazard ratio.
a

Model is adjusted for sex, race/ethnicity, randomization group, body mass index,
ibuprofen use 3 or more times/week, smoking status, and history of myocardial
infarction, stroke, hypertension, and diabetes.
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particularly with aspirin use 3 or more times per week. reduced risk of CRC mortality was only
associated with individuals with BMI 20 to 29.9 who reported aspirin use 3 or more times per week.
The efficacy of prophylactic aspirin use for prevention of cancer incidence and mortality has
been debated; however, the most evidence from prospective cohorts and secondary analyses from
clinical trials indicates a protective association with aspirin use. A 2016 systematic analysis of primary
and secondary cardiovascular prevention trials21 found reduced CRC incidence 10 to 19 years after
aspirin use initiation. This association persists among investigations of aspirin use and cancer
mortality. A 2011 systematic analysis of 8 clinical trials22 found that daily aspirin use was associated
with reduced risk of death of several cancers, with increased benefit associated with long-term use. A
similar association was observed in a 2018 cohort study23 of veterans in which aspirin users were
associated with reduced risk of CRC mortality compared with nonusers. This association was
additionally examined in the Cancer Prevention Study-II Nutrition Cohort,24 in which daily aspirin use
was associated with reduced overall cancer mortality. These observations are in contrast with data
from the ASPREE trial.13 However, the interpretation of the ASPREE results is limited owing a lack of
an association of aspirin with cancer and CRC incidence and the short duration of follow-up.25 With
additional follow-up, an association of aspirin with lower cancer incidence and death may have
emerged.26 In addition, a 2018 combined analysis of the NIH-AARP Diet and Health Study and the
PLCO Cancer Screening Trial27 reported decreased risk of all-cause, cancer, and cardiovascular
mortality associated with daily aspirin use. However, a dosage that exceeded 1 per day was
associated with an increased risk of mortality. These data also did not account for effect
modifications by BMI on mortality risk. Previous studies have also found that variables, such as BMI,
are associated with the efficacy of prophylactic aspirin. In a 2012 study of the Cancer Prevention
Study-II Nutrition Cohort,28 individuals with prediagnostic BMI 30 or higher were associated with
increased risk of all-cause and CRC death. A similar association was demonstrated across several
other cohort and case-control studies, cancers, and causes of death.27,29-31
The observation that BMI may be associated with efficacy of aspirin in individuals 65 years and
older is notable; however, our findings require further confirmation. Increasing rates of overweight
and obesity globally may substantially alter the population-based efficacy of cancer prevention
prophylatics.32 Studies have suggested that aspirin has reduced effectiveness as a primary
prevention modality among individuals who are obese owing to decreased bioavailability and
antithrombotic efficacy; however, this study did not find an association of overweight or obesity with
decreased efficacy.5,33-35 Therefore, although aspirin use is associated with benefit as a cancer
preventive agent, the changing characteristics of the global population may alter its efficacy and
must be considered along with age and risk of bleeding before recommending aspirin for cancer
prevention.

Limitations and Strengths
Our study has several limitations. First, this is a secondary analysis of a randomized intervention
(screening) trial with self-reported data on aspirin use. When collecting self-reported data, one must
be aware of the limitations to these data, such as underreporting parameters of interest and the
potential effect of this error in the analyses, such as biasing toward the null. For example, it is possible
that aspirin use was underreported if the participant was unaware that a given agent, based upon its
trade name, was classified as aspirin. Next, the information on aspirin use may be subject to
participant interpretation and measurement error. Regular use of aspirin was not defined in the BQ,
so participants could then have interpreted regular aspirin use differently, which may have affected
their categorization (eg, none, monthly, weekly, daily). Furthermore, the information collected
regarding aspirin dosage was limited. These issues may, in addition to confounding by unmeasured
covariates, help explain the lack of a dose-response association for mortality risk in the observed
data. Though there is substantial evidence documenting the association of frequent aspirin use with
cancer prevention, the biological effect of low frequency use (eg, 1-3 times per month) is uncertain.
Therefore, the noted risk reduction associated with this group may be due to unmeasured
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confounders. Along similar lines, it remains possible that individuals who reported low or no use of
aspirin were unable to tolerate aspirin use for an extended length of time, perhaps owing to risk of
bleeding or gastrointestinal injury, and may be inherently different than those who reported aspirin
use.36 Additionally, our analysis was focused on individuals in the PLCO Cancer Screening Trial cohort
who survived to and began follow-up at or after age 65 years. However, only a small percentage
(5.5%) of the PLCO cohort was ineligible for our study.
Although this study had several limitations, the research questions investigated examining the
associations among aspirin use, BMI, and mortality adds to our knowledge of modifiable factors
associated with cancer prevention efficacy. We were able to explore this question in a large,
prospective study with an extended follow-up period.

Conclusions
In this cohort study, we found a significant association of aspirin use with reduced all-cause, any
cancer, GI cancer, and CRC mortality among individuals 65 years and older in the PLCO Cancer
Screening Trial. Aspirin use was associated with reduced risk of all-cause and any cancer mortality,
and aspirin use 3 or more times per week was associated with reduced risk of GI cancer mortality and
CRC mortality when stratified by BMI. Future studies should further examine the association of BMI
with the efficacy of aspirin as a cancer preventive agent to adapt to the changing global
obesity trends.
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